vTv Therapeutics Inc (NASDAQ:VTVT) Expected to Announce Quarterly Sales of $1.69 Million

Wall Street brokerages expect vTv Therapeutics Inc (NASDAQ:VTVT) to announce $1.69 million in sales for the current quarter, according to Zacks. Two analysts have made estimates for vTv Therapeutics’ earnings, with the lowest sales estimate coming in at $880,000.00 and the highest estimate coming in at $2.50 million. vTv Therapeutics reported sales of $3.38 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 50%. The firm is expected to issue its next earnings report on Thursday, November 14th.

On average, analysts expect that vTv Therapeutics will report full-year sales of $6.16 million for the current financial year, with estimates ranging from $4.62 million to $7.70 million. For the next financial year, analysts forecast that the company will post sales of $6.38 million, with estimates ranging from $2.75 million to $10.00 million. Zacks’ sales averages are an average based on a survey of research firms that cover vTv Therapeutics.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.02. The business had revenue of $1.83 million for the quarter, compared to analyst estimates of $1.63 million.

Several research firms recently weighed in on VTVT. Northland Securities set a $8.00 price objective on shares of vTv Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Zacks Investment Research lowered shares of vTv Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of vTv Therapeutics in a research note on Friday, August 16th. Finally, ValuEngine raised shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd.

In related news, major shareholder Ronald O. Perelman purchased 606,061 shares of the business’s stock in a transaction on Wednesday, September 18th. The shares were purchased at an average price of $1.65 per share, with a total value of $1,000,000.65. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Ronald O. Perelman purchased 50,000 shares of the business’s stock in a transaction on Thursday, August 22nd. The stock was bought at an average cost of $1.38 per share, for a total transaction of $69,000.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 2,180,924 shares of company stock worth $3,273,751 in the last three months. 1.70% of the stock is owned by insiders.

An institutional investor recently raised its position in vTv Therapeutics stock. BlackRock Inc. raised its stake in vTv Therapeutics Inc (NASDAQ:VTVT) by 25.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 65,031 shares of the biotechnology company’s stock after buying an additional 13,305 shares during the quarter. BlackRock Inc. owned about 0.12% of vTv Therapeutics worth $93,000 at the end of the most recent reporting period. 1.64% of the stock is currently owned by hedge funds and other institutional investors.

vTv Therapeutics stock traded down $0.02 during midday trading on Wednesday, hitting $1.45. 124,316 shares of the stock were exchanged, compared to its average volume of 783,910. The company has a fifty day simple moving average of $1.44 and a two-hundred day simple moving average of $1.46. vTv Therapeutics has a 52 week low of $1.00 and a 52 week high of $4.59. The stock has a market capitalization of $78.49 million, a PE ratio of -2.10 and a beta of -3.61.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.

Recommended Story: What are gap-up stocks?

Get a free copy of the Zacks research report on vTv Therapeutics (VTVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.